芬尼酮在糖尿病慢性肾病中的作用——包括HFpEF或HFmrEF患者的现实见解。

IF 3.7 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann-Kathrin Schäfer, Michael J Koziolek, Manuel Wallbach
{"title":"芬尼酮在糖尿病慢性肾病中的作用——包括HFpEF或HFmrEF患者的现实见解。","authors":"Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann-Kathrin Schäfer, Michael J Koziolek, Manuel Wallbach","doi":"10.1002/ehf2.15424","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Finerenone, a highly selective non-steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This study aimed to investigate the safety and cardiac effects of finerenone in patients with DKD with or without HFpEF/HFmrEF in a real-world setting.</p><p><strong>Methods: </strong>Patients with DKD were prospectively enrolled and were treated with finerenone according to best clinical practice. Clinical, laboratory and echocardiographic assessments were performed before, 4 weeks and 6 months after starting finerenone.</p><p><strong>Results: </strong>Thirty-one patients with DKD were included. At baseline, patients had a typical risk profile with arterial hypertension (90.3%) and hyperlipoproteinemia (87.1%). Most patients were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (93.5%). Treatment with finerenone was safe and well tolerated: after 4 weeks, the glomerular filtration rate decreased slightly from 52 (43-78) mL/min/1.73 m<sup>2</sup> to 48.0 (39.0-71.0) mL/min/1.73 m<sup>2</sup> (P = 0.002 vs. baseline), but stabilized thereafter. Similarly, the median potassium value increased from 4.2 (3.8-4.5) mmol/L to 4.4 (4.2-4.8) mmol/L (P = 0.017) after 4 weeks, but remained stable thereafter [4.4 (4.1-4.6) mmol/L (P = 0.079)]. Only one patient (3.2%) had an unplanned hospitalization and concomitant hyperkalaemia up to 6.0 mmol/L. HFpEF/HFmrEF was frequently found in patients with DKD (71.0%), although most patients had a rather early stage with only mild symptoms and a median N-terminal pro B-type natriuretic peptide (NT-proBNP) value of 150.8 (54.5-325.7) ng/L. During treatment with finerenone, NT-proBNP and left ventricular mass index (LVMI) remained stable. In contrast, left atrial volume index (LAVI) decreased from baseline [31.2 (26.8-39.7) mL/m<sup>2</sup>] to 4 weeks follow-up [29.7 (20.8-33.6) mL/m<sup>2</sup>, P = 0.027] and decreased further after 6 months [26.6 (20.8-34.9) mL/m<sup>2</sup>, P = 0.029]. In the subgroup of patients with HFpEF/HFmrEF, E/e' decreased from 11.9 (8.7-14.5) at baseline to 9.9 (8.0-12.4) after 6 months (P = 0.043).</p><p><strong>Conclusions: </strong>In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.\",\"authors\":\"Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann-Kathrin Schäfer, Michael J Koziolek, Manuel Wallbach\",\"doi\":\"10.1002/ehf2.15424\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Finerenone, a highly selective non-steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This study aimed to investigate the safety and cardiac effects of finerenone in patients with DKD with or without HFpEF/HFmrEF in a real-world setting.</p><p><strong>Methods: </strong>Patients with DKD were prospectively enrolled and were treated with finerenone according to best clinical practice. Clinical, laboratory and echocardiographic assessments were performed before, 4 weeks and 6 months after starting finerenone.</p><p><strong>Results: </strong>Thirty-one patients with DKD were included. At baseline, patients had a typical risk profile with arterial hypertension (90.3%) and hyperlipoproteinemia (87.1%). Most patients were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (93.5%). Treatment with finerenone was safe and well tolerated: after 4 weeks, the glomerular filtration rate decreased slightly from 52 (43-78) mL/min/1.73 m<sup>2</sup> to 48.0 (39.0-71.0) mL/min/1.73 m<sup>2</sup> (P = 0.002 vs. baseline), but stabilized thereafter. Similarly, the median potassium value increased from 4.2 (3.8-4.5) mmol/L to 4.4 (4.2-4.8) mmol/L (P = 0.017) after 4 weeks, but remained stable thereafter [4.4 (4.1-4.6) mmol/L (P = 0.079)]. Only one patient (3.2%) had an unplanned hospitalization and concomitant hyperkalaemia up to 6.0 mmol/L. HFpEF/HFmrEF was frequently found in patients with DKD (71.0%), although most patients had a rather early stage with only mild symptoms and a median N-terminal pro B-type natriuretic peptide (NT-proBNP) value of 150.8 (54.5-325.7) ng/L. During treatment with finerenone, NT-proBNP and left ventricular mass index (LVMI) remained stable. In contrast, left atrial volume index (LAVI) decreased from baseline [31.2 (26.8-39.7) mL/m<sup>2</sup>] to 4 weeks follow-up [29.7 (20.8-33.6) mL/m<sup>2</sup>, P = 0.027] and decreased further after 6 months [26.6 (20.8-34.9) mL/m<sup>2</sup>, P = 0.029]. In the subgroup of patients with HFpEF/HFmrEF, E/e' decreased from 11.9 (8.7-14.5) at baseline to 9.9 (8.0-12.4) after 6 months (P = 0.043).</p><p><strong>Conclusions: </strong>In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.</p>\",\"PeriodicalId\":11864,\"journal\":{\"name\":\"ESC Heart Failure\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESC Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ehf2.15424\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15424","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:Finerenone是一种高度选择性的非甾体矿物皮质激素受体拮抗剂,被批准用于治疗慢性肾病(CKD)和2型糖尿病(糖尿病肾病,DKD)患者。芬尼酮降低了射血分数保持或轻度降低(HFpEF/HFmrEF)的心力衰竭患者的心力衰竭事件和心血管死亡的复合终点。本研究旨在研究在现实世界中,芬烯酮对伴有或不伴有HFpEF/HFmrEF的DKD患者的安全性和心脏效应。方法:前瞻性纳入DKD患者,根据最佳临床实践给予芬尼酮治疗。在开始使用芬芬酮前、4周和6个月分别进行临床、实验室和超声心动图评估。结果:纳入31例DKD患者。基线时,患者具有典型的动脉高血压(90.3%)和高脂蛋白血症(87.1%)风险。大多数患者使用钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂(93.5%)治疗。芬尼酮治疗安全且耐受性良好:4周后,肾小球滤过率从52 (43-78)mL/min/1.73 m2略微下降至48.0 (39.0-71.0)mL/min/1.73 m2(与基线相比P = 0.002),但此后稳定。同样,钾中值在4周后从4.2 (3.8-4.5)mmol/L上升到4.4 (4.2-4.8)mmol/L (P = 0.017),但此后保持稳定[4.4 (4.1-4.6)mmol/L (P = 0.079)]。只有1例患者(3.2%)有计划外住院并伴有高达6.0 mmol/L的高钾血症。HFpEF/HFmrEF常见于DKD患者(71.0%),但大多数患者早期发病,症状轻微,n端前b型利钠肽(NT-proBNP)中位值为150.8 (54.5-325.7)ng/L。在芬芬酮治疗期间,NT-proBNP和左心室质量指数(LVMI)保持稳定。相比之下,左房容积指数(LAVI)从基线[31.2 (26.8-39.7)mL/m2]下降至随访4周[29.7 (20.8-33.6)mL/m2, P = 0.027], 6个月后进一步下降[26.6 (20.8-34.9)mL/m2, P = 0.029]。在HFpEF/HFmrEF患者亚组中,E/ E′从基线时的11.9(8.7-14.5)降至6个月后的9.9 (8.0-12.4)(P = 0.043)。结论:在现实环境中,芬尼酮治疗DKD患者是安全且耐受性良好的,并可能改善心脏功能和结构参数。有必要进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF.

Purpose: Finerenone, a highly selective non-steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This study aimed to investigate the safety and cardiac effects of finerenone in patients with DKD with or without HFpEF/HFmrEF in a real-world setting.

Methods: Patients with DKD were prospectively enrolled and were treated with finerenone according to best clinical practice. Clinical, laboratory and echocardiographic assessments were performed before, 4 weeks and 6 months after starting finerenone.

Results: Thirty-one patients with DKD were included. At baseline, patients had a typical risk profile with arterial hypertension (90.3%) and hyperlipoproteinemia (87.1%). Most patients were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (93.5%). Treatment with finerenone was safe and well tolerated: after 4 weeks, the glomerular filtration rate decreased slightly from 52 (43-78) mL/min/1.73 m2 to 48.0 (39.0-71.0) mL/min/1.73 m2 (P = 0.002 vs. baseline), but stabilized thereafter. Similarly, the median potassium value increased from 4.2 (3.8-4.5) mmol/L to 4.4 (4.2-4.8) mmol/L (P = 0.017) after 4 weeks, but remained stable thereafter [4.4 (4.1-4.6) mmol/L (P = 0.079)]. Only one patient (3.2%) had an unplanned hospitalization and concomitant hyperkalaemia up to 6.0 mmol/L. HFpEF/HFmrEF was frequently found in patients with DKD (71.0%), although most patients had a rather early stage with only mild symptoms and a median N-terminal pro B-type natriuretic peptide (NT-proBNP) value of 150.8 (54.5-325.7) ng/L. During treatment with finerenone, NT-proBNP and left ventricular mass index (LVMI) remained stable. In contrast, left atrial volume index (LAVI) decreased from baseline [31.2 (26.8-39.7) mL/m2] to 4 weeks follow-up [29.7 (20.8-33.6) mL/m2, P = 0.027] and decreased further after 6 months [26.6 (20.8-34.9) mL/m2, P = 0.029]. In the subgroup of patients with HFpEF/HFmrEF, E/e' decreased from 11.9 (8.7-14.5) at baseline to 9.9 (8.0-12.4) after 6 months (P = 0.043).

Conclusions: In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信